Coherus Oncology, Inc.
27
9
10
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
7.4%
2 terminated/withdrawn out of 27 trials
83.3%
-3.2% vs industry average
19%
5 trials in Phase 3/4
50%
5 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (27)
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Role: collaborator
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Role: collaborator
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Role: collaborator
Window of Opportunity in Preserving Laryngeal Function Trial
Role: collaborator
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Role: lead
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Role: lead
Study of CHS-114 in Participants With Advanced Solid Tumors
Role: lead
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Role: lead
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Role: collaborator
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Role: lead
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Role: collaborator
PDT For Induction Therapy For Head And Neck Cancer
Role: collaborator
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Role: lead
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Role: collaborator
Toripalimab With Chemotherapy for Sinus Cancer
Role: collaborator
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Role: lead
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Role: lead
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Role: lead
Study of SRF617 in Patients With Advanced Solid Tumors
Role: lead
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
Role: lead